Zentalis Pharmaceuticals 13G Filing Shows Eventide Asset Management, LLC Holds 11.07% Stake In Co
Portfolio Pulse from Benzinga Newsdesk
Eventide Asset Management, LLC has disclosed a 11.07% stake in Zentalis Pharmaceuticals, according to a 13G filing with the SEC.
October 10, 2023 | 7:48 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Eventide Asset Management's 11.07% stake in Zentalis Pharmaceuticals could potentially influence the company's stock price.
The acquisition of a significant stake by Eventide Asset Management could potentially influence Zentalis Pharmaceuticals' stock price. However, the direction of the impact is uncertain and depends on various factors including market perception of Eventide's investment.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100